Sun Pharma enters into strategic agreement with Samsung BioLogics

Sun Pharma appoints Samsung BioLogics to manufacture Tildrakizumab

Sun Pharmaceutical Industries and Samsung BioLogics announced a strategic long-term manufacturing agreement for Tildrakizumab. The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung BioLogics.

According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. Filings for this novel investigational biologic has been accepted for review by the U.S. Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017). The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea. The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential.

Powered by Capital Market - Live News